Toro Haroldo, Zhao Wei, Breedlove Cassandra, Zhang Zhenyu, Yu Qingzhong, Van Santen Vicky
Avian Dis. 2014 Mar;58(1):83-9. doi: 10.1637/10641-081613-Reg.1.
We developed a recombinant Newcastle disease virus (NDV) LaSota (rLS) expressing the infectious bronchitis virus (IBV) S2 gene (rLS/IBV.S2). The recombinant virus showed somewhat-reduced pathogenicity compared to the parental lentogenic LaSota strain but effectively elicited hemagglutination inhibition antibodies against NDV and protected chickens against lethal challenge with virulent NDV/CA02. IBV heterotypic protection was assessed using a prime-boost approach with a commercially available attenuated IBV Massachusetts (Mass)-type vaccine. Specific-pathogen-free chickens primed ocularly with rLS/IBV.S2 at 4 days of age and boosted with Mass at 18 days of age were completely protected against challenge at 41 days of age with a virulent Ark-type strain. In a second experiment, we compared protection conferred by priming with rLS/IBV.S2 and boosting with Mass (rLS/IBV.S2+Mass) versus priming and boosting with Mass (Mass+Mass). We also modified the timing of vaccination to prime at 1 day of age and boost at 12 days of age. Challenge with virulent Ark was performed at 21 days of age. Based on clinical signs, both vaccinated groups appeared equally protected against challenge compared to unvaccinated challenged chickens. Viral loads in lachrymal fluids of birds receiving rLS/IBV.S2+Mass showed a clear tendency of improved protection compared to Mass+Mass; however, the difference did not achieve statistical significance. A significant difference (P < 0.05) was determined between these groups regarding incidence of detection of challenge IBV RNA in the trachea; viral RNA was detected in 50% of rLS/IBV.S2+Mass-vaccinated chickens while chickens vaccinated with Mass+Mass and unvaccinated challenged controls showed 84 and 90% incidence of IBV RNA detection in the trachea, respectively. These results demonstrate that overexposing the IBV S2 to the chicken immune system by means of a vectored vaccine, followed by boost with whole virus, protects chickens against IBV showing dissimilar S1.
我们构建了一种表达传染性支气管炎病毒(IBV)S2基因的重组新城疫病毒(NDV)LaSota株(rLS/IBV.S2)。与亲代弱毒LaSota株相比,重组病毒的致病性有所降低,但能有效诱导针对NDV的血凝抑制抗体,并保护鸡只免受强毒NDV/CA02的致死性攻击。采用市售的减毒IBV Massachusetts(Mass)型疫苗进行初免 - 加强免疫方案来评估IBV异型保护作用。4日龄时经眼内接种rLS/IBV.S2进行初免、18日龄时用Mass疫苗加强免疫的无特定病原体鸡,在41日龄时能完全抵抗强毒Ark型毒株的攻击。在第二个实验中,我们比较了用rLS/IBV.S2初免并用Mass加强免疫(rLS/IBV.S2+Mass)与用Mass初免和加强免疫(Mass+Mass)所提供的保护作用。我们还调整了免疫接种时间,在1日龄时进行初免,12日龄时进行加强免疫。在21日龄时用强毒Ark进行攻毒。基于临床症状,与未接种疫苗而受到攻击的鸡相比,两个接种疫苗组在抵抗攻击方面表现出同等程度的保护。与Mass+Mass组相比,接受rLS/IBV.S2+Mass免疫的鸡的泪液中的病毒载量显示出明显的保护作用改善趋势;然而,差异未达到统计学显著性。在气管中检测到攻击IBV RNA的发生率方面确定了这两组之间存在显著差异(P < 0.05);在接种rLS/IBV.S2+Mass的鸡中有50%检测到病毒RNA,而接种Mass+Mass的鸡和未接种疫苗而受到攻击的对照鸡在气管中检测到IBV RNA的发生率分别为84%和90%。这些结果表明,通过载体疫苗将IBV S2过度暴露于鸡免疫系统,随后用全病毒进行加强免疫,可保护鸡只免受具有不同S1的IBV的侵害。